1. Bressler NM Dolan CM Fine J Marceau C Chang TS Vision-specific quality of life at 12 months in predominantly classic neovascular AMD in ANCHOR: a phase III trial of ranibizumab and verteporfin PDT http://www.evrs.org/pages/2006/Scientifis%20Sessions_abstracts/Sunday/512.pdf,
2. Ranibizumab versus verteporfin for neovascular age-related macular degeneration;Brown;New England Journal of Medicine,2006
3. Eyetech Pharmaceuticals Inc Pfizer Inc Pegaptanib sodium injection in the treatment of neovascular age-related macular degeneration http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4053b1.htm
4. FDA Macugen (pegaptanib sodium injection) for the treatment of neovascular age-related macular degeneration http://www.fda.gov/ohrms/dockets/ac/04/briefing/2004-4053b1.htm
5. Pegaptanib 1-year systemic safety results from a safety-pharmacokinetic trial in patients with neovascular age-related macular degeneration;Apte;Ophthalmology,2007